West Pharmaceutical Services Inc (WST)

$373.78

+4.95

(+1.34%)▲

Market is closed - opens 7 PM, 05 Oct 2023

Insights on West Pharmaceutical Services Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 686.9M → 753.8M (in $), with an average increase of 3.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 103.0M → 155.1M (in $), with an average increase of 18.1% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 42.9% return, outperforming this stock by 1.7%

Performance

  • $366.95
    $374.21
    $373.78
    downward going graph

    1.83%

    Downside

    Day's Volatility :1.94%

    Upside

    0.11%

    downward going graph
  • $205.66
    $415.73
    $373.78
    downward going graph

    44.98%

    Downside

    52 Weeks Volatility :50.53%

    Upside

    10.09%

    downward going graph

Returns

PeriodWest Pharmaceutical Services IncSector (Health Care)S&P500
3 Months
-2.17%
-3.2%
-5.1%
6 Months
5.96%
-2.7%
3.1%
1 Year
41.23%
0.8%
11.6%
3 Years
28.23%
22.3%
26.3%

Highlights

Market Capitalization
27.4B
Book Value
$37.17
Dividend Share
0.75
Dividend Yield
0.2%
Earnings Per Share (EPS)
6.87
PE Ratio
53.94
PEG Ratio
4.06
Wall Street Target Price
400.71
Profit Margin
18.1%
Operating Margin TTM
24.51%
Return On Assets TTM
12.49%
Return On Equity TTM
20.06%
Revenue TTM
2.9B
Revenue Per Share TTM
38.52
Quarterly Revenue Growth YOY
-2.3%
Gross Profit TTM
1.1B
EBITDA
829.0M
Diluted Eps TTM
6.87
Quarterly Earnings Growth YOY
-0.17
EPS Estimate Current Year
7.85
EPS Estimate Next Year
8.83
EPS Estimate Current Quarter
1.93
EPS Estimate Next Quarter
1.87

Analyst Recommendation

Buy
    64%Buy
    35%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for West Pharmaceutical Services Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
8
7
Hold
5
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 7.2%

Current $373.78
Target $400.71

Company Financials

FY17Y/Y Change
Revenue
1.6B
↑ 5.96%
Net Income
150.7M
↑ 4.94%
Net Profit Margin
9.42%
↓ 0.1%
FY18Y/Y Change
Revenue
1.7B
↑ 7.4%
Net Income
206.9M
↑ 37.29%
Net Profit Margin
12.05%
↑ 2.63%
FY19Y/Y Change
Revenue
1.8B
↑ 7.13%
Net Income
241.7M
↑ 16.82%
Net Profit Margin
13.14%
↑ 1.09%
FY20Y/Y Change
Revenue
2.1B
↑ 16.69%
Net Income
346.2M
↑ 43.24%
Net Profit Margin
16.13%
↑ 2.99%
FY21Y/Y Change
Revenue
2.8B
↑ 31.89%
Net Income
661.8M
↑ 91.16%
Net Profit Margin
23.37%
↑ 7.24%
FY22Y/Y Change
Revenue
2.9B
↑ 1.95%
Net Income
585.9M
↓ 11.47%
Net Profit Margin
20.3%
↓ 3.07%
Q1 FY22Q/Q Change
Revenue
720.0M
↓ 1.48%
Net Income
173.8M
↑ 17.67%
Net Profit Margin
24.14%
↑ 3.93%
Q2 FY22Q/Q Change
Revenue
771.3M
↑ 7.12%
Net Income
188.5M
↑ 8.46%
Net Profit Margin
24.44%
↑ 0.3%
Q3 FY22Q/Q Change
Revenue
686.9M
↓ 10.94%
Net Income
120.6M
↓ 36.02%
Net Profit Margin
17.56%
↓ 6.88%
Q4 FY22Q/Q Change
Revenue
708.7M
↑ 3.17%
Net Income
103.0M
↓ 14.59%
Net Profit Margin
14.53%
↓ 3.03%
Q1 FY23Q/Q Change
Revenue
716.6M
↑ 1.11%
Net Income
140.0M
↑ 35.92%
Net Profit Margin
19.54%
↑ 5.01%
Q2 FY23Q/Q Change
Revenue
753.8M
↑ 5.19%
Net Income
155.1M
↑ 10.79%
Net Profit Margin
20.58%
↑ 1.04%
FY17Y/Y Change
Total Assets
1.9B
↑ 8.51%
Total Liabilities
582.9M
↓ 2.72%
FY18Y/Y Change
Total Assets
2.0B
↑ 6.23%
Total Liabilities
582.6M
↓ 0.05%
FY19Y/Y Change
Total Assets
2.3B
↑ 18.32%
Total Liabilities
768.2M
↑ 31.86%
FY20Y/Y Change
Total Assets
2.8B
↑ 19.32%
Total Liabilities
939.3M
↑ 22.27%
FY21Y/Y Change
Total Assets
3.3B
↑ 18.61%
Total Liabilities
978.4M
↑ 4.16%
Q1 FY22Q/Q Change
Total Assets
3.3B
↓ 0.58%
Total Liabilities
968.5M
↓ 1.01%
Q2 FY22Q/Q Change
Total Assets
3.4B
↑ 2.03%
Total Liabilities
937.3M
↓ 3.22%
Q3 FY22Q/Q Change
Total Assets
3.3B
↓ 1.34%
Total Liabilities
846.0M
↓ 9.74%
Q1 FY23Q/Q Change
Total Assets
3.7B
-
Total Liabilities
947.4M
-
Q2 FY23Q/Q Change
Total Assets
3.7B
↓ 1.45%
Total Liabilities
922.9M
↓ 2.59%
FY17Y/Y Change
Operating Cash Flow
263.3M
↑ 20.01%
Investing Cash Flow
-133.6M
↓ 24.0%
Financing Cash Flow
-109.0M
↓ 4.3%
FY18Y/Y Change
Operating Cash Flow
288.6M
↑ 9.61%
Investing Cash Flow
-100.8M
↓ 24.55%
Financing Cash Flow
-80.7M
↓ 25.96%
FY19Y/Y Change
Operating Cash Flow
367.2M
↑ 27.23%
Investing Cash Flow
-228.0M
↑ 126.19%
Financing Cash Flow
-36.8M
↓ 54.4%
FY20Y/Y Change
Operating Cash Flow
472.5M
↑ 28.68%
Investing Cash Flow
-179.5M
↓ 21.27%
Financing Cash Flow
-137.1M
↑ 272.55%
FY21Y/Y Change
Operating Cash Flow
584.0M
↑ 23.6%
Investing Cash Flow
-253.1M
↑ 41.0%
Financing Cash Flow
-168.1M
↑ 22.61%
Q1 FY22Q/Q Change
Operating Cash Flow
151.2M
↓ 5.97%
Investing Cash Flow
-68.3M
↓ 11.76%
Financing Cash Flow
-172.7M
↑ 2685.48%
Q2 FY22Q/Q Change
Operating Cash Flow
173.1M
↑ 14.48%
Investing Cash Flow
-66.0M
↓ 3.37%
Financing Cash Flow
-36.2M
↓ 79.04%
Q3 FY22Q/Q Change
Operating Cash Flow
168.9M
↓ 2.43%
Investing Cash Flow
-59.1M
↓ 10.45%
Financing Cash Flow
-75.2M
↑ 107.73%
Q1 FY23Q/Q Change
Operating Cash Flow
138.1M
↓ 40.16%
Investing Cash Flow
-82.1M
-
Financing Cash Flow
-71.0M
-
Q2 FY23Q/Q Change
Operating Cash Flow
169.2M
↑ 22.52%
Investing Cash Flow
-82.1M
↑ 0.0%
Financing Cash Flow
-176.8M
↑ 149.01%

Technicals Summary

Sell

Neutral

Buy

West Pharmaceutical Services Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-8.63%
5.96%
41.23%
28.23%
208.41%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-6.38%
13.09%
42.92%
22.1%
55.85%
Resmed Inc.
Resmed Inc.
-6.04%
-34.35%
-36.79%
-15.35%
31.7%
Becton, Dickinson And Company
Becton, Dickinson And Company
-5.12%
4.29%
9.25%
8.72%
2.18%
Alcon Ag
Alcon Ag
-9.19%
6.36%
19.54%
27.84%
27.84%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
53.94
53.94
4.06
7.85
0.2
0.12
0.0
37.17
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
74.68
74.68
3.27
5.59
0.12
0.07
0.0
33.82
Resmed Inc.
Resmed Inc.
23.74
23.74
1.74
6.52
0.24
0.12
0.01
28.08
Becton, Dickinson And Company
Becton, Dickinson And Company
46.61
46.61
2.31
12.22
0.06
0.03
0.01
89.4
Alcon Ag
Alcon Ag
112.22
112.22
NA
2.75
0.02
0.02
0.0
40.44
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$27.4B
208.41%
53.94
18.1%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$103.6B
55.85%
74.68
21.38%
Resmed Inc.
Resmed Inc.
Buy
$21.3B
31.7%
23.74
21.25%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$74.8B
2.18%
46.61
8.74%
Alcon Ag
Alcon Ag
Buy
$40.5B
27.84%
112.22
3.99%

Institutional Holdings

  • Vanguard Group Inc

    12.12%

  • BlackRock Inc

    10.79%

  • Bank of New York Mellon Corp

    4.66%

  • State Street Corporation

    4.43%

  • T. Rowe Price Associates, Inc.

    3.84%

  • Apg All Pensions Group

    3.06%

Corporate Announcements

  • West Pharmaceutical Services Inc Dividends March,2023

    In the quarter ending March,2023. West Pharmaceutical Services Inc has declared dividend of $0.19

    Read More

Company Information

west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.

Organization
West Pharmaceutical Services Inc
Employees
10700
CEO
Mr. Eric M. Green
Industry
Health Technology

Discover More

FAQs